CredoScientia - Bibliothèque

Conversion therapy for stage IV gastric cancer.

Thérapies de Conversion

Hu, C., Terashima, M., & Cheng, X. (2023). Conversion therapy for stage IV gastric cancer.. Sci Bull (Beijing), 68(7), 653-656. https://doi.org/10.1016/j.scib.2023.03.011

15/04/2023 Lire →

Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study.

BACKGROUND: Recently, many studies have shown that the progress of conversion therapy can provide surgical opportunities for patients with advanced gastric cancer (GC) and bring survival benefits. How…

Thérapies de Conversion

Deng, Y. Y., Jiang, D. Y., Zhu, P. F., Lu, H., Liu, Q., Zhang, X., Pan, S. Y., Chen, Z. L., & Yang, L. (2023). Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study.. World J Surg Oncol, 21(1), 129. https://doi.org/10.1186/s12957-023-02973-3

11/04/2023 Lire →

Management of locally advanced intrahepatic cholangiocarcinoma: a narrative review.

BACKGROUND AND OBJECTIVE: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary hepatic malignancy, which has increased in incidence over the past decades. While surgical resection is the sta…

Thérapies de Conversion

Bressler, L., Bath, N., Manne, A., Miller, E., & Cloyd, J. M. (2023). Management of locally advanced intrahepatic cholangiocarcinoma: a narrative review.. Chin Clin Oncol, 12(2), 15. https://doi.org/10.21037/cco-22-115

01/04/2023 Lire →

Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy.

Transarterial chemoembolization (TACE) has been standard treatment for intermediate-stage hepatocellular carcinoma (HCC). However, all intermediate-stage HCC patients did not benefit from TACE treatme…

Thérapies de Conversion

Hatanaka, T., Yata, Y., Naganuma, A., & Kakizaki, S. (2023). Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy.. Cancers (Basel), 15(6). https://doi.org/10.3390/cancers15061798

16/03/2023 Lire →

An exploratory human study of superstable homogeneous lipiodol-indocyanine green formulation for precise surgical navigation in liver cancer.

The clinical applications of transcatheter arterial embolization (TAE) conversion therapy combined with hepatectomy have been severely restricted by ill-defined tumoral boundaries and miniscule hidden…

Thérapies de Conversion

He, P., Xiong, Y., Luo, B., Liu, J., Zhang, Y., Xiong, Y., Su, S., Fang, C., Peng, Y., Cheng, H., Chu, C., Mao, J., Li, J., Li, B., Yin, Z., Tian, J., & Liu, G. (2023). An exploratory human study of superstable homogeneous lipiodol-indocyanine green formulation for precise surgical navigation in liver cancer.. Bioeng Transl Med, 8(2), e10404. https://doi.org/10.1002/btm2.10404

01/03/2023 Lire →

Anti-PD-1 plus anti-angiogenesis combined with chemotherapy in patients with HER2-negative advanced or metastatic gastric cancer: a multi-institutional retrospective study.

BACKGROUND: Immunotherapy plus chemotherapy have been confirmed to be effective in treating advanced or metastatic gastric cancer (GC). Anti- programmed death-1 (PD-1) plus antiangiogenic agents have …

Thérapies de Conversion

Xu, T., Wang, W., Bao, R., Xia, X., Zhang, J., Huang, M., Chen, X., Wang, R., Zhang, H., Liu, X., Li, Q., & Shu, Y. (2023). Anti-PD-1 plus anti-angiogenesis combined with chemotherapy in patients with HER2-negative advanced or metastatic gastric cancer: a multi-institutional retrospective study.. J Gastrointest Oncol, 14(1), 175-186. https://doi.org/10.21037/jgo-23-73

28/02/2023 Lire →

Banning conversion therapy for trans people.

Thérapies de Conversion

Motmans, J., Cannoot, P., & T'Sjoen, G. (2023). Banning conversion therapy for trans people.. BMJ, 380, 341. https://doi.org/10.1136/bmj.p341

22/02/2023 Lire →

Current Status of Lymphangiogenesis: Molecular Mechanism, Immune Tolerance, and Application Prospect.

The lymphatic system is a channel for fluid transport and cell migration, but it has always been controversial in promoting and suppressing cancer. VEGFC/VEGFR3 signaling has long been recognized as a…

Thérapies de Conversion

Deng, H., Zhang, J., Wu, F., Wei, F., Han, W., Xu, X., & Zhang, Y. (2023). Current Status of Lymphangiogenesis: Molecular Mechanism, Immune Tolerance, and Application Prospect.. Cancers (Basel), 15(4). https://doi.org/10.3390/cancers15041169

11/02/2023 Lire →

Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy?

BACKGROUND: Hepatocellular carcinoma (HCC) is the sixth most common cancer globally, with limited therapies and unsatisfactory prognosis once in the advanced stages. With promising advances in locoreg…

Thérapies de Conversion

Jiang, C., Sun, X. D., Qiu, W., Chen, Y. G., Sun, D. W., & Lv, G. Y. (2023). Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy?. Hepatobiliary Pancreat Dis Int, 22(1), 7-13. https://doi.org/10.1016/j.hbpd.2022.10.006

01/02/2023 Lire →

Conversion Surgery After Encorafenib Plus Cetuximab for Chemorefractory V600E-mutated Colorectal Cancer With Para-aortic Lymph Node Metastases.

BACKGROUND/AIM: Mutant BRAF V600E colorectal cancer accounts for 5% of metastatic colorectal cancers, and it has a poor response to systemic chemotherapy and a poor prognosis. However, combination tre…

Thérapies de Conversion

Kawata, A., Miyamoto, Y., Fukubayashi, K., Horio, T., Miyamoto, H., Ogawa, K., Ouchi, M., Tanaka, Y., & Baba, H. (2023). Conversion Surgery After Encorafenib Plus Cetuximab for Chemorefractory V600E-mutated Colorectal Cancer With Para-aortic Lymph Node Metastases.. In Vivo, 37(4), 1797-1801. https://doi.org/10.21873/invivo.13269

01/01/2023 Lire →

Safety and efficacy of laparoscopic digestive tract nutrition reconstruction combined with conversion therapy for patients with unresectable and obstructive gastric cancer.

BACKGROUND: To explore the safety, efficacy, and survival benefits of laparoscopic digestive tract nutrition reconstruction (LDTNR) combined with conversion therapy in patients with unresectable gastr…

Thérapies de Conversion

Ye, R., Wang, C., Hu, B., & Guan, G. (2023). Safety and efficacy of laparoscopic digestive tract nutrition reconstruction combined with conversion therapy for patients with unresectable and obstructive gastric cancer.. Front Oncol, 13, 1175580. https://doi.org/10.3389/fonc.2023.1175580

01/01/2023 Lire →

Case report: A ERBB3 mutation develops in a gallbladder cancer patient carrying BRCA1 mutation after effective treatment with olaparib.

BACKGROUND: Gallbladder cancer (GBC) is highly lethal and resistant to most chemotherapeutic drugs. GBC was reported to carry multiple genetic mutations such as TP53, K-RAS, and ERBB2/3. Here, we unex…

Thérapies de Conversion

Yang, J. X., Jia, Z. Y., Liu, F. T., Wu, W. G., Li, X. C., Zou, L., Li, H. F., Zhang, F., Bao, R. F., Peng, S. Y., Lau, W. Y., Liu, Y., Li, M. L., & Liu, Y. B. (2023). Case report: A ERBB3 mutation develops in a gallbladder cancer patient carrying BRCA1 mutation after effective treatment with olaparib.. Front Oncol, 13, 1078388. https://doi.org/10.3389/fonc.2023.1078388

01/01/2023 Lire →